Efrati and his team performed a study involving 35 healthy independent older adults. His research team concluded that HBOT significantly lengthened telomeres and decreased levels of senescent cells. Furthermore, Efrati’s trial used double-blind random controlled testing – considered by medical practitioners to be the gold standard of medical testing.
HBOT therapy targets many of the biological mechanisms underlying aging, including shortening of telomeres, cell senescence and DNA mutations. Furthermore, HBOT helps improve mitochondrial function while relieving oxidative stress and aiding angiogenesis.
